Strategic Advisors’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-24,436
Closed -$6.21M 204
2021
Q4
$6.21M Sell
24,436
-1,439
-6% -$421K 0.88% 30
2021
Q3
$9.96M Sell
25,875
-5
-0% -$1.84K 2.14% 10
2021
Q2
$6.08M Buy
25,880
+11,560
+81% +$2.07M 1.58% 16
2021
Q1
$1.88M Hold
14,320
0.54% 41
2020
Q4
$1.65M Buy
+14,320
New +$1.45M 0.48% 47

Other funds holding MRNA

Strategic Advisors's MRNA Position: Q1 2022 in Review

Strategic Advisors sold out of Moderna (MRNA) in Q1 2022, closing a stake of 24,436 shares — an estimated $6.21M sold.

Strategic Advisors first reported a position in MRNA in Q4 2020 and held it in 5 quarters. The position peaked at $9.96M in Q3 2021. 1,006 funds tracked by Wall St. Rank hold MRNA as of Q1 2022.

  • Strategic Advisors reported no remaining Moderna position as of Q1 2022 after selling out during the quarter.
  • Strategic Advisors sold 24,436 Moderna shares in Q1 2022, an estimated $6.21M.
  • Strategic Advisors first reported a position in Moderna in Q4 2020 and held it in 5 quarters.
  • Strategic Advisors's Moderna position peaked at $9.96M in Q3 2021.
  • 1,006 funds tracked by Wall St. Rank held Moderna as of Q1 2022.

Based on Strategic Advisors's 13F filing for Q1 2022, filed 10 May 2022.